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On the occasion of the publication of the results of
Syst-Eur Phase 2 [1], we wish to pay a special tribute
to the pioneers of this trial, the late Professor Antoon
Amery, and Professor Thomas Weihrauch.
These two outstanding clinical and pharmacologically
orientated scientists happened to meet on a aeroplane
back in 1986, soon after the publication of the EWPHE
trial [2]. This meeting, where Antoon Amery unfolded
his preliminary plan for a new study in elderly subjects
with isolated systolic hypertension (later to be named
Syst-Eur) received an enthusiastic response from Tho-
mas Weihrauch, and the two of them immediately got
down to business. It was agreed that such a (placebo-
controlled) study would most likely allow the then new
generation of antihypertensive drugs to demonstrate
their potential value in preventing hypertensive end-
organ damage. This might fill the information gap
versus the proven value of diuretics and -blockers in
that regard and, at the same time, provide support for
the then questionable concept of treating elderly in-
dividuals with isolated systolic hypertension. (The
Systolic Hypertension in the Elderly Program, started
in the USA, was also intended for the latter purpose
but did not include the new-generation drugs).
From a pathophysiological point of view, Amery and
Weihrauch both favoured the use of a dihydropyridine
calcium antagonist as the first-line active drug regarding
elderly hypertensives. Weihrauch added another di-
mension to their deliberations by referring to a recently
published paper in which it was shown that [3H]-
nitrendipine in the rat brain preferentially binds to
areas that, in man particularly, are affected by Alzhei-
mer’s disease: the superficial cortex, thalamus and
hippocampus [3]. That feature supposedly might add a
specific benefit in elderly hypertensives. Hence, the
choice fell on this particular calcium antagonist, as has
subsequently been justified in the course of the Syst-
Eur substudy on cognitive deterioration [4].
The Syst-Eur project required a large group of partici-
pating centres throughout Europe (including Israel),
and hence elaborate preparations. The first patients
were randomized in 1989, and the protocol was pub-
lished in 1991 with Professor Antoon Amery as first-
named author [5]. As fate would have it, soon after-
wards, Antoon fell victim to a progressive and fatal
illness, and died in 1994. In that critical episode, he
conveyed his co-ordinating task in the Leuven Syst-Eur
centre to one of us (J.A.S), withdrawing from further
authorship.
Professor Thomas Weihrauch was never identified as
an author on any Syst-Eur publication, by his own
volition. Because of his formal association with the
main sponsor of the trial, he felt it was proper to remain
in the background. We respected that, although his
enduring loyalty to the investigators, as well as his
purely scientific contributions to the evolution of the
project over the years, would certainly have entitled
him, at least in our view, to a prominent co-authorship.
His devotion to Syst-Eur became particularly decisive
in one particular episode when we faced the end of the
randomized phase of the trial, which was originally
predetermined to be its termination [6]. In that period,
we became increasingly worried that our trial popu-
lation in less privileged European countries might
become cut-off from appropriate continuation of anti-
hypertensive treatment after formal closure of the trial,
and hence the supply of trial drugs. As a matter of
course, this applied particularly to those patients who
were randomized to the active treatment arm, but
hardly less so to those whose actual treatment require-
ments deviated from the per protocol purpose of
placebo treatment. The ideal solution to this ethical
dilemma would be to organize a transition period
during which the entire trial population would be
offered active trial medication, maintaining the logistics
of supply and supervision. In that way, the local
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investigators could extend their current observation and
prepare themselves and their patients for long-term
routine treatment. Of course, this would be a revolu-
tionary way of taking leave of a trial population in a
civilized fashion, but also one which by and large would
pose an excessive and unforeseen financial burden on
the trial’s main sponsoring drug house. Faced with this
existential dilemma, Thomas Weihrauch fully rose to
the challenge not only by unreservedly sharing our
ethical concerns, but also by offering an intellectual
and pragmatic rationale on the part of the pharma-
ceutical industry. He argued that a substantial exten-
sion of observation might well provide a unique
opportunity to settle once and for all question of a
cancer scare and allied warnings in relation to chronic
calcium channel blockade, as issued from certain cor-
ners [7]. That argument clinched the ‘deal’ and allowed
us to continue [8], and virtually doubled the observa-
tion period for our trial population, much to the latter’s
benefit and the ultimate proficiency of Syst-Eur.
The Syst-Eur investigators owe a warm tribute to
Thomas Weihrauch for his unswerving loyalty to the
project which he created together with Antoon Amery
almost 20 years ago. We feel committed to do so
in writing on behalf of the Syst-Eur community, at
the risk of embarrassing our friend Thomas’ modest
personality.
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